FDA approved this novel, dual-targeted treatment for type 2 diabetes. The manufacturer reported that this drug proved more effective in clinical trials than other therapies evaluated. This injection could improve blood sugar control in adults with type 2 diabetes who practise diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies. Furthermore, it was more effective than other currently available therapies to reduce the body weight. That’s why, this injection is called dual-targeted treatment for type 2 diabetes. Source: US FDA news release. Accessed 21/02/2023.
PharmaMedical Trend Analysis (PMTA)
Medical Pharmaceutical News